Description
INDICATIONS AND USAGE:
Imjudo (tremelimumab) is a cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) blocking antibody indicated only in combination with Imfinzi (durvalumab), for the treatment of adult patients with unresectable hepatocellular carcinoma (uHCC).
DOSAGE FORMS & STRENGTHS:
Injection: 300 mg/15 mL (20 mg/mL) solution in a single-dose vial.
Additional information
| Brand | Imjudo |
|---|---|
| Generic name | Tremelimumab infusion |
| Form | Parenteral |
| Strength | 300mg/15ml |
| Manufacturer | AstraZeneca |
| Documents | Either PO or prescription |
| Storage | 2-8°C temperature |
Related products
-
+ wishlist+ compare
BRUKINSA capsules 80mg
Original price was: $3,889.00.$3,500.00Current price is: $3,500.00.Add to cart
Reviews
There are no reviews yet.